



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2023/S-LDF110

August 10, 2023

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001.

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Ref: Scrip Code No. 524768

With reference to the above subject, please be informed that the Board of Directors at its meeting held today, has transacted the following business.

1. The Board has considered and approved the Un Audited Standalone Financial Results of the company for the first quarter ended June 30, 2023. pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Un Audited Financial Results of the Company for the first quarter ended June 30, 2023 is attached herewith and will be made available on the website of the Company: <http://www.ebnl.org>, in due compliance with the Listing Regulations. The results is also filed in XBRL format.
2. The Board took on record the Limited Review Report issued by the Statutory Auditors, attached herewith.
3. Declaration pursuant to Regulation 33 (3) (d) of SEBI [LODR] Regulations, 2015.
4. The Board finalised the date of the Annual General Meeting i.e. 29.09.2023.
5. General discussion about other matters as per the agenda of the meeting.
6. The Board elected Mr. Srinivasa Raghavan Mathurakavi Ayyangar as the Chairman of the Company. He is now the Chairman and the Managing Director of the Company.
7. The approved the appointment the new Statutory Auditors

You are kindly requested to take same on record.

Thanking you,
Yours faithfully,
For Emmessar Biotech & Nutrition Limited


Jeyavel B. Nadar
Executive Director
DIN No. 08163899



Encl: Financial Results, Limited Review Report

MEETING COMMENCED AT 12:15pm AND ENDED AT 3:30pm.

Regd. Office & Factory: Plot No. T-3/2, MIDC Area, Talaja – 410208. Dist. Raigad. Maharashtra.
Email: enquiries@ebnl.org Website: www.ebnl.org



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org

Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Annexure - I

Reconstitution of Committees

I. AUDIT COMMITTEE	<ol style="list-style-type: none">01. Mr. Milind Sitaram Desai - Chairman02. Mr. Anantharama S. Subramanian - Member03. Mr. Srinivasa Raghavan Mathurakavi Ayyangar – Member
II. NOMINATION & REMUNERATION COMMITTEE	<ol style="list-style-type: none">01. Mr. Milind S. Desai - Chairman02. Mr. Anantharama S. Subramanian - Member03. Mrs. Rajalakshmi S. Raghavan - Member

Yours faithfully,

For Emmessar Biotech & Nutrition Limited

Jeyavel B. Nadar
Executive Director
DIN No. 08163899





EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2022/S-LDF110B

August 10, 2023

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001.

Dear Sir / Madam,

Sub: Outcome of the Board Meeting.

Intimation for change in Directorate pursuant to Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Ref: Scrip Code No. 524768

Pursuant to Regulation 30 and other applicable regulations of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held on Thursday, August 10, 2023, on the recommendations of the Nomination and Remuneration Committee, has approved the appointment of Srinivasa Raghavan Mathurakavi Ayyangar as the Chairman of the Company. He is now the Chairman and the Managing Director of the Company.

The Board has also reconstituted the following Committees: as per Annexure I


1. Audit Committee – Chairman
2. NRC - Member

You are kindly requested to take same on record.

Thanking you,

Yours faithfully,

For Emmessar Biotech & Nutrition Limited


Jeyavel B. Nadar
Executive Director
DIN No. 08163899



Encl: Reconstitution of Committee Members – Annexure-I

Regd. Office & Factory: Plot No. T-3/2, MIDC Area, Taloja – 410208. Dist. Raigad. Maharashtra.
Email: enquiries@ebnl.org Website: www.ebnl.org

EMMESSAR BIOTECH & NUTRITION LIMITED

Regd Office: T-3/2, MIDC, Talaja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229


UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2023

		(Rupees in Lakhs)			
Sr. No	Particulars	Quarter Ended		Year Ended	
		30.06.2023 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited
	PART A				
1	Revenue from Operations	6.77	31.64	20.78	101.92
2	Other Income	45.71	41.59	44.09	175.07
	Total Income (1 + 2)	52.48	73.23	64.87	276.99
	PART B				
3	Expenses				
	Cost of material consumed	1.62	2.07	1.49	6.88
	Purchase of Stock-trade	0.00	11.68	7.00	37.66
	Change in Inventories of Finished goods	-0.03	-0.14	-0.33	-4.56
	Employee Benefit Expenses	22.26	20.21	19.36	83.71
	Depreciation & Amortisation of Assets	2.44	2.37	2.28	9.36
	Other Expenditure	10.25	13.11	8.42	47.25
	Total Expenses	36.53	49.30	38.21	180.30
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	15.94	23.93	26.66	96.69
5	Exceptional items	0.00	0.00	0.00	0.00
6	Profit / (loss) before tax (4 - 5)	15.94	23.93	26.66	96.69
7	Tax Expenses				
	1. Current Tax	-4.50	5.00	0.00	-14.91
	2. Deferred Tax	-5.95	0.30	-7.00	-21.18
	3. MAT Credit available	0.00	-13.55	0.00	-13.77
	4. Excess/short provision of earlier years	0.00	4.01	0.00	3.55
8	Net Profit / (loss) after tax (6 - 7)	5.49	19.69	19.53	50.38
9	Other Comprehensive Income	0.00	-0.82	0.00	-0.82
10	Total comprehensive income and Other Comprehensive Income	5.49	18.87	19.53	49.56
11	Paid-up Equity Share Capital	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Earning per Shares				
	1. Basic	0.11	0.38	0.39	0.99
	2. Diluted	0.11	0.38	0.39	0.99

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 10th August 2023 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates two segments ie. Healthcare and rent on leasehold land during this quarter.
- No Investor Complaint was received for the quarter ended 30th June 2023




 Srinivasa Raghavan Mathurakavi Ayyangar
 Chairman & Managing Director
 DIN: 00090266

Mumbai
10-Aug-23

EMMESSAR BIOTECH & NUTRITION LIMITED

Regd Office: T-3/2, MIDC, Talaja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2023

[Rs. In Lakhs]

	Quarter Ended			Year Ended	
	30.06.2022 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited	
1. Segment Revenue					
Healthcare	6.77	31.64	20.78	101.92	
Rent on Leasehold Land	37.16	37.16	37.16	148.64	
Others	8.55	4.43	6.93	26.43	
Total:	52.48	73.23	64.87	276.99	
Less: Inter Segment Revenue	-	-	-	-	
Net Sales / Income from Operations	52.48	73.23	64.87	276.99	
Segment Results (Profit / Loss) tax					
Healthcare	4.29	16.97	11.86	58.61	
Rent on Leasehold Land	36.93	37.16	36.93	148.64	
Others	8.55	4.43	6.93	26.43	
Total:	49.77	58.56	55.72	233.68	
Less:					
Interest	-	-	-	-	
Other Unallocable Expenditure (Net off)	33.83	34.63	29.19	136.99	
Total Profit before Tax & Exceptional items	15.94	23.93	26.53	96.69	
Capital Employed (Segment Assets - Segment Liabilities)					
Healthcare	12.60	13.62	6.55	13.62	
Leasehold Land	-0.95	-0.72	-0.95	-0.72	
Others	653.97	646.42	635.83	646.42	
Total:	665.62	659.32	641.43	659.32	

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 10th August 2023

Mumbai
10-Aug-23

By order of the Board
Srinivasa Raghavan Mathurakavi Ayyangar
Chairman & Managing Director
DIN: 00090266



Tel : 2200 4465, 2206 7440
Fax : 91-22- 2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai – 400 020

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF

Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter ended June 30, 2023.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Mumbai
Date: August 10, 2023

For V. Sankar Aiyar & Co.,
Chartered Accountants
(FRN. 109208W)

ASHA
JAYANTIB
HAI PATEL

Digitally signed by
ASHA JAYANTIBHAI
PATEL
Date: 2023.08.10
13:39:51 +05'30'

Asha Patel
Partner
(M.No. 166048)
UDIN: 23166048BGUTGK7424